苦参素与干扰素联合治疗慢性乙型肝炎的临床观察

目的观察苦参素与干扰素-α2b用于拉米夫定治疗慢性乙型肝炎失败后再治疗的疗效。方法64例符合条件的患者,随机分为2个组:A组32例,仍用贺普丁100mg/d继续治疗12个月;B组32例改用苦参素并干扰素-α2b500万U/d肌注半月,后改为隔日1次,疗程12个月。观察治疗前,治疗后2个月、5个月、8个月、12个月肝功能、乙肝病毒血清标志物(HBV-M)、HBVDNA变化情况。结果各组疗程完成后,对HBVDNA及HBeAg阴转率苦参素与干扰素较对照组差异显著(P<0.05)。结论拉米夫定治疗慢性乙型肝炎失败后改用苦参素与干扰素联合抗病毒治疗,效果较为满意。

Objective To observe the effect on chronic hepatitis B treated by IFN-α2b combination with oxymatrine due to failed treadment with lamivudine. Methods Sixty four patients who fit to condition were divided into groups randomly, A group, 32 cases, still with lamivudine 100 mg orally, once daily for 12 months. B group, 32 cases being treated by IFN-α2b combination with oxymatrine, INF-α2b 500 MIU was initiated, once daily for half month, intramuscularly, laterly every other day for 12 months. To study the liver function, HBVDNA and HBV marker before treatment or after treatment in two, five, eight, and twelve month respectively. Results After treatment, there is a obviously significance (P<0.05) between IFN combining oxymatrine and lamivudine lonely in sero conversion rates of HBVDNA and HBeAg. Conclusions The effectives of chronic hepatitis B treated by IFN α combination with oxymatrine is more comfortable due to failed treatment by lamivudine.